Home › Funds › MAVERICK CAPITAL LTD › NAMS

MAVERICK CAPITAL LTD position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

MAVERICK CAPITAL LTD reported holding 3,267,802 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$110.7M, representing 1.03% of its reported portfolio and ranking #32 among its reported holdings. MAVERICK CAPITAL LTD has disclosed NAMS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)3.27M sh
Reported value held$110.75M
Portfolio Weight1.03%
First reportedQ4 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MAVERICK CAPITAL LTD's NAMS position evolved

MAVERICK CAPITAL LTD first disclosed a stake in NAMS in Q4 2024 at 350,005 shares (US$9.0M). The position peaked in Q2 2026 at 3,267,802 shares, worth US$110.7M. Across 7 filings, MAVERICK CAPITAL LTD increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,267,802 shares valued at US$110.7M — an increase of 1,081,400 shares quarter over quarter.. Notable position changes include a 57% increase in Q1 2025 (shares fell 8% over the following quarter), a 179% increase in Q2 2025 (shares rose 50% over the following quarter), a 49% increase in Q2 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 350.00K $9.00M New
Q1 2025 549.47K $11.25M Add
Q2 2025 1.53M $27.74M Add
Q3 2025 1.50M $42.80M Reduce
Q4 2025 1.89M $66.45M Add
Q1 2026 2.19M $69.99M Add
Q2 2026 3.27M $110.75M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has MAVERICK CAPITAL LTD held NAMS?

MAVERICK CAPITAL LTD has disclosed NAMS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is MAVERICK CAPITAL LTD's current position in NAMS?

As of Q2 2026, MAVERICK CAPITAL LTD holds 3.27M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $110.75M, representing 1.03% of its reported portfolio and ranking #32.

Has MAVERICK CAPITAL LTD been buying or selling NAMS?

In the latest 13F filing (Q2 2026), MAVERICK CAPITAL LTD increased its position in NAMS. The position peaked in Q2 2026 at 3.27M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.